Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.
06-29-2021 | ADA 2021 | Conference coverage | News
Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.
Long-term dulaglutide use may reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes, particularly those with underlying cardiovascular disease, shows an exploratory analysis of REWIND data.